TNFRSF17 and plasma cell myeloma: More recently, the FDA approved three additional CAR T cell therapies: lisocabtagene maraleucel (Breyanzi) and brexucabtagene autoleucel (Tecartus) against CD19 in B-cell malignancies, and idecabtagene vicleucel (Abecma) against the B-cell maturation antigen (BCMA, also known as TNFRSF17) in myeloma [19–21].